Articles by John

I have been building forums to promote the life sciences community for over 10 years. I enjoy exploring the issues, individuals and companies impacting the life/med/health tech community, and celebrating the innovators, entrepreneurs and policy makers who are actively working to build the community.


Is Amgen The Next Big Split?

First Abbott split and created AbbVie, then Baxter with Baxalta, is Amgen up next? I am placing best the new spin off will be called Pmgen. Hedge fund manager Daniel Loeb is lending his voice to the chorus of investors who believe Amgen ($AMGN) would do better as two companies. And his firm, Third Point,…


Philips Looking to HealthTech to Bolster Bottom Line

Philips ($PHG) shed as much as 4% in early trading as continued manufacturing problems and intellectual property litigation as well as weakness in Russia and China weighed on investor confidence after it reported third-quarter results. The conglomerate had a net loss of €103 million ($132 million) on sales of €5.5 billion in the third quarter,…


FDA Extends Exclusivity for Certain Combo-Meds

What’s two extra years of exclusivity worth? Enough to spark a legal fight. The FDA posted new guidance on its website Friday, awarding certain combo meds 5 years of exclusivity compared with the previous three. Drugmakers had lobbied for the change, but the timing–and the wording–are bound to be controversial.


Gambro Acquisition Fuels Baxter’s Growth Before Split

The acquisition of dialysis company Gambro last September continues to fuel Baxter International’s ($BAX) sales growth as it preps to spin out its biopharma division in 2015. But despite some stop-gap measures, it’s not likely that Baxter will actually be able to meet the demand for its dialysis products until additional manufacturing capacity opens up in 2016.

Copyright © 2014 WhiteCityNews, All rights reserved.